Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
FWB: CWY0
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
16
July
2024
Clearmind Obtains IND Approval from the FDA to Start Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
Read More
16
July
2024
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
Read More
12
July
2024
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
Read More
28
June
2024
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
Read More
11
June
2024
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
Read More
10
May
2024
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
Read More
7
May
2024
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Read More
30
April
2024
Clearmind Applies to Cease Being a Reporting Issuer in Canada
Read More
17
April
2024
Clearmind Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Read More
10
April
2024
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Read More
9
April
2024
Clearmind Medicine CEO Issues Letter to Shareholders
Read More
27
March
2024
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
Read More
13
March
2024
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
Read More
13
March
2024
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
Read More
27
February
2024
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
Read More
Previous
Next